Short Interest in abrdn Life Sciences Investors (NYSE:HQL) Decreases By 37.6%

abrdn Life Sciences Investors (NYSE:HQL) was the target of a significant decline in short interest in the month of January. As of January 30th, there was short interest totaling 37,925 shares, a decline of 37.6% from the January 15th total of 60,767 shares. Approximately 0.1% of the shares of the company are short sold. Based on an average daily volume of 113,249 shares, the short-interest ratio is currently 0.3 days. Based on an average daily volume of 113,249 shares, the short-interest ratio is currently 0.3 days. Approximately 0.1% of the shares of the company are short sold.

Institutional Trading of abrdn Life Sciences Investors

A number of institutional investors have recently modified their holdings of the stock. WNY Asset Management LLC grew its position in abrdn Life Sciences Investors by 3.4% in the second quarter. WNY Asset Management LLC now owns 24,955 shares of the company’s stock valued at $320,000 after acquiring an additional 821 shares during the last quarter. Kingsview Wealth Management LLC increased its position in abrdn Life Sciences Investors by 2.8% during the 2nd quarter. Kingsview Wealth Management LLC now owns 36,743 shares of the company’s stock worth $471,000 after purchasing an additional 1,000 shares in the last quarter. Flagship Harbor Advisors LLC lifted its stake in abrdn Life Sciences Investors by 0.3% in the 2nd quarter. Flagship Harbor Advisors LLC now owns 341,959 shares of the company’s stock valued at $4,380,000 after purchasing an additional 1,082 shares during the last quarter. Samalin Investment Counsel LLC boosted its position in abrdn Life Sciences Investors by 6.7% in the second quarter. Samalin Investment Counsel LLC now owns 21,782 shares of the company’s stock valued at $279,000 after buying an additional 1,366 shares in the last quarter. Finally, Advisors Asset Management Inc. boosted its holdings in shares of abrdn Life Sciences Investors by 0.9% during the 2nd quarter. Advisors Asset Management Inc. now owns 160,173 shares of the company’s stock valued at $2,052,000 after acquiring an additional 1,487 shares in the last quarter. 32.21% of the stock is currently owned by institutional investors.

abrdn Life Sciences Investors Stock Up 1.3%

Shares of NYSE HQL traded up $0.21 during midday trading on Friday, reaching $17.00. 71,550 shares of the company traded hands, compared to its average volume of 133,418. abrdn Life Sciences Investors has a 12 month low of $10.55 and a 12 month high of $17.80. The stock’s 50-day simple moving average is $16.95 and its 200-day simple moving average is $15.88.

abrdn Life Sciences Investors Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 31st. Stockholders of record on Friday, February 20th will be given a $0.56 dividend. The ex-dividend date of this dividend is Friday, February 20th. This is a boost from abrdn Life Sciences Investors’s previous quarterly dividend of $0.50. This represents a $2.24 dividend on an annualized basis and a dividend yield of 13.2%.

abrdn Life Sciences Investors Company Profile

abrdn Life Sciences Investors (NYSE: HQL) is a closed-end management investment company that seeks capital appreciation through investment in the life sciences sector. Established in 1994, the trust focuses on equity and equity-related securities of companies engaged in biotechnology, pharmaceuticals, medical devices, diagnostics and related fields. Its closed-end structure allows portfolio managers to maintain a stable pool of capital, pursue long-term investment strategies and employ leverage when deemed appropriate.

The fund’s portfolio spans both public and private companies, with an emphasis on businesses driving innovation in drug development, gene therapy, precision medicine and healthcare technology.